RheaVita markets an innovative continuous freeze-drying technology for (bio)pharmaceutical products. Their manufacturing approach saves time and money, guarantees product quality, and offers operations greater flexibility compared to traditional batch freeze-drying. RheaVita sells single vial units for research and development, as well as full GMP systems. They develop freeze-drying processes rapidly with limited product consumption, designing optimal formulations for vaccines and biopharmaceuticals such as mRNA-LNPs, viral vectors, and monoclonal antibodies.

Services include:
– Contract Development and Manufacturing (CDMO)
– Single vial units for R&D
– Full GMP systems
– Process development
– Formulation design

RheaVita is dedicated to providing cutting-edge solutions that enhance the efficiency and quality of pharmaceutical production. For further information, please visit rheavita.com.